PANZEPAM

PANZEPAM is a pharmaceutical tablet formulation containing Paroxetine 12.5 mg in controlled-release (CR) form and Clonazepam 0.5 mg. It is included in SupriMeda’s psychiatric product portfolio and is presented for professional pharmaceutical reference, product identification, and institutional procurement.

The formulation combines two active pharmaceutical ingredients with distinct pharmacological classifications. Paroxetine belongs to the selective serotonin reuptake inhibitor (SSRI) class, while Clonazepam belongs to the benzodiazepine class. The controlled-release designation refers to the Paroxetine component of the formulation. These details help healthcare professionals, pharmacists, and pharmaceutical procurement teams distinguish PANZEPAM from other products containing similar ingredients or different strengths.

PANZEPAM is supplied in a tablet dosage form, with a listed pack configuration of 10 × 10 tablets. For accurate pharmaceutical cataloguing, product name, active ingredients, strengths, dosage form, and pack details should be maintained consistently across product listings, purchase enquiries, and institutional records.